ZLABZai Lab
About Zai Lab
Zai Lab (HKEX:9688), (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to meet the needs of patients across a broad range of diseases, including oncology, autoimmune disorders, and infectious diseases. The company emphasizes research and collaboration, aiming to bring cutting-edge treatments to underserved populations. Through its projects, Zai Lab endeavors to push the boundaries of medical science, striving to improve outcomes and enhance the quality of life for patients worldwide. Its objectives center around expanding its product portfolio, advancing its clinical trials, and fostering partnerships to accelerate the global availability of its therapeutic solutions.
What is ZLAB known for?
Snapshot
Public US
Ownership
2013
Year founded
529
Employees
Shanghai, China
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
People’s Republic of China
Products and/or services of Zai Lab
- Omvikopa (Niraparib) for the treatment of ovarian cancer, providing a targeted therapy option for patients with specific genetic mutations.
- Optune, a novel electric field therapy for glioblastoma, offering a non-invasive treatment option to improve survival rates in brain cancer patients.
- Repotrectinib, a next-generation ROS1/NTRK inhibitor targeting a broad range of mutations in non-small cell lung cancer and other solid tumors.
- Margetuximab, an innovative monoclonal antibody for HER2-positive breast cancer, designed to provide a more effective treatment option compared to standard therapies.
- Regorafenib, a kinase inhibitor for the treatment of colorectal cancer and gastrointestinal stromal tumors, offering hope to patients with advanced stages of the disease.
- Zejula (Niraparib) for treating endometrial cancer, expanding the use of Niraparib beyond ovarian cancer to benefit a wider range of patients.
Zai Lab executive team
- Dr. Ying Du Ph.D.Founder, Chairperson & CEO
- Mr. Joshua L. SmileyPresident & COO
- Dr. Rafael G. Amado M.D.President and Head of Global Research & Development
- Dr. Yajing Chen Ph.D.Chief Financial Officer
- Mr. Frazor Titus Edmondson III, J.D.Chief Legal Officer & Corporate Secretary
- Ms. Christine ChiouSenior VP & Head of Investor Relations
- Dr. James Yan DABT, M.D., Ph.D.Chief Operating Officer of R&D
- Mr. Tong ZhuChief Commercial Officer of Greater China
- Dr. Shan He Ph.D.Senior VP & Chief Business Officer